| Followers | 9 |
| Posts | 1671 |
| Boards Moderated | 0 |
| Alias Born | 11/10/2020 |
Wednesday, March 24, 2021 9:05:48 AM
We would love to but remember, they don't take live calls. This question was asked more than 6 times and each time he side stepped and gave fluff. But at least the calls went from saving $2k to over 20k according to him. All transparent companies start with pre screened questions. Duh.
Speaking of dead horses, how many times will people talk about hidden messages in obscure links? Medicare codes, SRO lists, manufacturing sites, Amerax hiring, CYTO hiring etc etc.
Best part of the call was his commenting on Philippines sales. Big PR, stock moves up increasing market cap by over $1b and they had 1 patient ask who then declined since he got better on his own. 2nd best was him blaming the DSMC for not adjusting the age groups. How many longs pumped this based on no recommendations were needed?
Everyone loves their own brand but it is sad to see people fall for the same tricks over and over and over and over. M/M is over, S/C is over, they are already planting seeds for when LH and NASH are over. cf16 and cd17 ARE THE NEW toy. In 5 months, they will start with a random cancer trial or even MS as cd16 and cd17 come to a close and certain failure.
Interesting how many hear take paid promotion articles and Reddit as gospel but when people post actual SEC docs they say its fake and not a big deal.
Breeze, your 8k call for Monday with OJ was not right. Where is Black-ops that so many here listened to and praised?
Where is the FIFE SEC docs? They are now 2 months behind. I need to go back and rear the agreement but I am curious if these lawsuits trigger a default clause for FIFE and Samsung. If that is true, a real dilution tsunami is coming and another blow with Samsung.
Speaking of dead horses, how many times will people talk about hidden messages in obscure links? Medicare codes, SRO lists, manufacturing sites, Amerax hiring, CYTO hiring etc etc.
Best part of the call was his commenting on Philippines sales. Big PR, stock moves up increasing market cap by over $1b and they had 1 patient ask who then declined since he got better on his own. 2nd best was him blaming the DSMC for not adjusting the age groups. How many longs pumped this based on no recommendations were needed?
Everyone loves their own brand but it is sad to see people fall for the same tricks over and over and over and over. M/M is over, S/C is over, they are already planting seeds for when LH and NASH are over. cf16 and cd17 ARE THE NEW toy. In 5 months, they will start with a random cancer trial or even MS as cd16 and cd17 come to a close and certain failure.
Interesting how many hear take paid promotion articles and Reddit as gospel but when people post actual SEC docs they say its fake and not a big deal.
Breeze, your 8k call for Monday with OJ was not right. Where is Black-ops that so many here listened to and praised?
Where is the FIFE SEC docs? They are now 2 months behind. I need to go back and rear the agreement but I am curious if these lawsuits trigger a default clause for FIFE and Samsung. If that is true, a real dilution tsunami is coming and another blow with Samsung.
Recent CYDY News
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
